Introducing Dx:Revenue - Precision Medicine Intelligence for Business Development Teams

LEARN MORE
Posts From the monthly archives: "June 2013"

Some interesting points raised in a NY Times editorial yesterday regarding Myriad’s true underlying value being in its database of mutations. In a paper referenced by the editorial the authors describe Myriad’s database of BRCA1/2 mutations and the value of the company’s ability to understand the phenotypic significance of variations that…(Read More)

Unmasking ‘Invisible’ Drug Trials – ScienceInsider. Do drug companies and other commercial entities have an obligation to report the results of the clinical trials they have sponsored? Interesting question, that. Most trials for novel therapeutics and diagnostics are paid for almost entirely by the sponsors, but knowing trial results would almost certainly present opportunities for…(Read More)